How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,934 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2012 Clinical Trials

82. A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) - Full Text (...) and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01717287 Recruitment Status : Completed First Posted : October 30, 2012 Results First Posted : July 29, 2014 Last Update Posted : August 21, 2018 Sponsor: Merck Sharp & Dohme Corp

2012 Clinical Trials

83. Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. (Abstract)

community-acquired pneumonia (CAP) in children aged two months to 59 months.We searched CENTRAL (2015, Issue 1), MEDLINE (1966 to January week 4, 2015) and EMBASE (1974 to February 2015).Randomised controlled trials (RCTs) evaluating the efficacy of short-course (two to three days) versus long-course (five days) intravenous antibiotic therapy for severe pneumonia in children aged two months to 59 months. We excluded children with any other debilitating disease, including those infected with HIV and we (...) Short-course versus long-course intravenous therapy with the same antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. Pneumonia remains the single leading cause of childhood mortality, causing an estimated 1.3 million childhood deaths each year in children under the age of five years. The greater burden of disease occurs in low-income countries, where medical resources and hospital-based management are poor. The World Health Organization (WHO) current

2015 Cochrane

84. Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey. Full Text available with Trip Pro

Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey. Viral load testing is considered the gold standard for monitoring HIV treatment; however, given its high cost, some patients cannot afford viral load testing if this testing is not subsidized. Since foreign aid for HIV/AIDS in Vietnam is rapidly decreasing, we sought to assess willingness to pay (WTP) for viral load and CD4 cell count tests (...) among HIV-positive patients, and identified factors that might inform future co-payment schemes.A multi-site cross-sectional survey was conducted with 1133 HIV-positive patients on antiretroviral therapy (ART) in Hanoi and Nam Dinh. Patients' health insurance coverage, quality of life, and history of illicit drug use were assessed. A contingent valuation approach was employed to measure patients' WTP for CD4 cell count and viral load testing.HIV-positive patients receiving ART at provincial sites

2017 PLoS ONE

85. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients Full Text available with Trip Pro

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients Background: With the availability of direct acting antiviral treatment for hepatitis C (HCV), HIV and HCV co-infected patients show comparable treatment responses to HCV-monoinfected patients. An 8-week course of sofosbuvir/ledipasvir (SOF/LDV) is highly effective for the treatment of HCV genotype 1 infection in treatment-naïve mono-infected patients with HCV viral (...) loads <6 million IU/ml. There is limited data on the efficacy of this 8-week HCV treatment regimen in HIV-infected individuals with similar viral loads. Methods: The study was a retrospective review of HIV-infected adults coinfected with HCV genotype 1 for whom an 8-week course of SOF/LDV was prescribed by providers at two clinics in the Yale-New Haven Health system from November 1, 2014 until April 30, 2016. Treatment efficacy was assessed as the proportion of treatment initiators who achieved

2018 F1000Research

86. The Effect of Monitoring Viral Load and Tracing Patients Lost to Follow-up on the Course of the HIV Epidemic in Malawi: A Mathematical Model Full Text available with Trip Pro

The Effect of Monitoring Viral Load and Tracing Patients Lost to Follow-up on the Course of the HIV Epidemic in Malawi: A Mathematical Model Antiretroviral therapy (ART) reduces HIV transmission, but treated patients may again become infectious. We used a mathematical model to determine whether ART as prevention is more effective if viral load (VL) is routinely monitored and patients lost to follow-up (LTFU) traced.We simulated ART cohorts to parameterize a deterministic transmission model (...) prevented 0.8% (1.4%), tracing prevented 0.3% (0.5%), and uninterrupted treatment prevented 5.5% (9.9%) of HIV infections. Failed scale-up resulted in 25% more infections than the Universal ART scenarios, whereas Test&Treat resulted in 7%-8% less.Test&Treat reduces transmission of HIV, despite individual cases of treatment failure and ART interruption. Whereas viral load monitoring and tracing have only a minor impact on transmission, interventions that aim to minimize treatment interruptions can

2018 Open forum infectious diseases

87. Sexual Risk Behaviors of Patients with HIV/AIDS over the Course of Antiretroviral Treatment in Northern Vietnam Full Text available with Trip Pro

Sexual Risk Behaviors of Patients with HIV/AIDS over the Course of Antiretroviral Treatment in Northern Vietnam Antiretroviral therapy (ART) improves the health and well-being of people living with the human immunodeficiency virus (HIV, PLWH), and reduces their risk of transmitting the virus to sexual partners. However, patterns of sexual risk behavior among HIV-positive patients taking ART in Vietnam remain largely unknown. In this study, we sought to examine sexual risk behaviors (...) and their associated factors among HIV-positive patients receiving ART in northern Vietnam. The socio-demographic characteristics, ART use, health status, and sexual behaviors of 1133 patients taking ART in the Hanoi and Nam Dinh provinces were explored through face-to-face interviews. There were 63.5% of patients who had one sex partner, while 3.6% and 5.6% of patients had sexual intercourse with casual partners or sex workers, respectively, in the previous 12 months. Most participants tended to use condoms more

2018 International journal of environmental research and public health

88. Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. Full Text available with Trip Pro

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. Individuals lacking immune recovery during suppressive cART will still represent a clinical issue in the years to come, given the high proportion of HIV-infected subjects introducing therapy late in the course of disease. Understanding the mechanisms underlying poor CD4+ T-cell gain is crucial for the correct clinical (...) management of individuals in this context.An HIV-infected subject with poor CD4+ T-cell gain in the course of suppressive antiretroviral therapy was extensively investigated to identify the mechanisms behind inadequate CD4+ reconstitution. In particular, we studied the phenotype of circulating T-cells, interleukin-7 signaling in peripheral blood and bone marrow, gut function and microbial translocation markers as well as the composition of the faecal microbiota. Numerous therapeutic interventions ranging

2018 BMC Infectious Diseases

89. Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial. Full Text available with Trip Pro

Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial. We performed a phase 2 noninferiority trial examining the early fungicidal activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana.Human immunodeficiency virus (HIV)-infected adults with CM were randomized to (i) L-AmB 10 mg/kg on day 1 (single dose); (ii) L-AmB 10 mg/kg on day (...) )/mL/day.Eighty participants were enrolled. EFA for daily L-AmB was -0.41 log10 CFU/mL/day (standard deviation, 0.11; n = 17). Difference in mean EFA from control was -0.11 (95% CI, -.29 to .07) log10 CFU/mL/day faster with single dose (n = 16); -0.05 (95% CI, -.20 to .10) log10 CFU/mL/day faster with 2 doses (n = 18); and -0.13 (95% CI, -.35 to .09) log10 CFU/mL/day faster with 3 doses (n = 18). EFA in all short-course arms was noninferior to control. Ten-week mortality was 29% (n = 23

2018 Clinical Infectious Diseases Controlled trial quality: predicted high

90. Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1 Full Text available with Trip Pro

Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1 Delineating the key early events that lead to the development of broadly neutralizing anti-HIV-1 antibodies during natural infection may help guide the development of immunogens and vaccine regimens to prevent HIV-1 infection. In this study, we monitored two HIV-1-positive subjects, VC20013 and VC10014, over the course of infection from (...) maturation was occurring as breadth was developing. Our findings illustrate one potential mechanism by which bNAbs develop during natural infection in which an epitope target is acquired very early on during the course of infection but require time and maturation to develop into broadly neutralizing activity.One major goal of HIV-1 vaccine research is the development of a vaccine that can elicit broadly neutralizing antibodies (bNAbs). Although no such vaccine exists, bNAbs develop in approximately 20

2014 Journal of virology

91. Effectiveness Trial of Community-Based I Choose Life-Africa Human Immunodeficiency Virus Prevention Program in Kenya. Full Text available with Trip Pro

Effectiveness Trial of Community-Based I Choose Life-Africa Human Immunodeficiency Virus Prevention Program in Kenya. We measured the effectiveness of a human immunodeficiency virus (HIV) prevention program developed in Kenya and carried out among university students. A total of 182 student volunteers were randomized into an intervention group who received a 32-hour training course as HIV prevention peer educators and a control group who received no training. Repeated measures assessed HIV (...) -related attitudes, intentions, knowledge, and behaviors four times over six months. Data were analyzed by using linear mixed models to compare the rate of change on 13 dependent variables that examined sexual risk behavior. Based on multi-level models, the slope coefficients for four variables showed reliable change in the hoped for direction: abstinence from oral, vaginal, or anal sex in the last two months, condom attitudes, HIV testing, and refusal skill. The intervention demonstrated evidence

2014 The American journal of tropical medicine and hygiene Controlled trial quality: uncertain

92. PRO 140 for Human Immunodeficiency Virus Infection

PRO 140 for Human Immunodeficiency Virus Infection PRO 140 for Human Immunodeficiency Virus Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. PRO 140 for Human Immunodeficiency Virus Infection (...) Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: PRO 140 2103: A Phase 2a, Randomized Study of PRO 140 by Subcutaneous Injection in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection Study Start Date : September 2014 Actual Primary Completion Date : February 2015 Actual Study Completion Date : February 2015 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator

2014 Clinical Trials

93. Catalogue of infection control and hospital hygiene courses in the European Union ? 2016

Catalogue of infection control and hospital hygiene courses in the European Union ? 2016 www.ecdc.europa.eu Catalogue of infection control and hospital hygiene courses in the European Union 2016 TECHNICAL DOCUMENT ECDC TECHNICAL DOCUMENT Catalogue of infection control and hospital hygiene courses in the European Union 2016 ii This course catalogue was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Carmen Varela Santos, and produced (...) Hartemann (Vandoeuvre-lès-Nancy, France), Jette Holt (Statens Serum Institut, Copenhagen, Denmark), Smilja Kalenic (University of Zagreb, Croatia), Walter Popp (HyKoMedGmbH, Dortmund/Lünen, Germany) and Gaetano Privitera (University of Pisa, Italy). Acknowledgements We would like to thank the following individuals for their contributions in evaluating the infection control and hospital hygiene courses: Ana Budimir (Croatia); Brian Kristensen (Denmark); Pascal Astagneau (France); Outi Lyytikäinen

2017 European Centre for Disease Prevention and Control - Technical Guidance

94. Human Immunodeficiency Virus Infection (Overview)

Human Immunodeficiency Virus Infection (Overview) Pediatric HIV Infection: Practice Essentials, Background, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LW92ZXJ2aWV3 processing (...) > Pediatric HIV Infection Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Overview Practice Essentials Since the first cases of human immunodeficiency virus (HIV) infection were identified, the number of children infected with HIV has risen dramatically in developing countries, the result of an increased number of HIV-infected women of childbearing age in these areas. HIV is a retrovirus and can

2014 eMedicine Pediatrics

95. Human Immunodeficiency Virus Infection (Treatment)

Human Immunodeficiency Virus Infection (Treatment) Pediatric HIV Infection Treatment & Management: Approach Considerations, Overview of Antiretroviral Therapy, Prophylaxis and Treatment of Opportunistic Infections Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LXRyZWF0bWVudA== processing > Pediatric HIV Infection Treatment & Management Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Treatment Approach Considerations ART is the mainstay in human immunodeficiency virus (HIV) treatment. Appropriate antiretroviral therapy (ART) and treatment of specific infections and malignancies are critical in treating patients who are HIV positive. Intervening early may

2014 eMedicine Pediatrics

96. Human Immunodeficiency Virus Infection (Follow-up)

Human Immunodeficiency Virus Infection (Follow-up) Pediatric HIV Infection Treatment & Management: Approach Considerations, Overview of Antiretroviral Therapy, Prophylaxis and Treatment of Opportunistic Infections Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LXRyZWF0bWVudA== processing > Pediatric HIV Infection Treatment & Management Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Treatment Approach Considerations ART is the mainstay in human immunodeficiency virus (HIV) treatment. Appropriate antiretroviral therapy (ART) and treatment of specific infections and malignancies are critical in treating patients who are HIV positive. Intervening early may

2014 eMedicine Pediatrics

97. Human Immunodeficiency Virus Infection (Diagnosis)

Human Immunodeficiency Virus Infection (Diagnosis) Pediatric HIV Infection: Practice Essentials, Background, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LW92ZXJ2aWV3 processing (...) > Pediatric HIV Infection Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Overview Practice Essentials Since the first cases of human immunodeficiency virus (HIV) infection were identified, the number of children infected with HIV has risen dramatically in developing countries, the result of an increased number of HIV-infected women of childbearing age in these areas. HIV is a retrovirus and can

2014 eMedicine Pediatrics

98. Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

and tolerability of cabozantinib (XL184) (cabozantinib-s-malate) as a single agent in solid tumor participants with human immunodeficiency virus (HIV) infection and to determine the maximal tolerated dose (MTD) in this patient population. SECONDARY OBJECTIVES: I. To investigate possible pharmacokinetic interactions between cabozantinib and antiretroviral therapy in persons with HIV infection. II. To investigate the effects of therapy on participant immune status and HIV viral load. III. To preliminarily assess (...) treatment ] Binomial proportions and their 95% confidence intervals will be used. Effects of therapy on human immunodeficiency virus (HIV) viral load [ Time Frame: Up to 30 days after completion of study treatment ] A repeated measures analysis of variance will be used to assess the effect of cabozantinib-s-malate on HIV viral loads across time points. Analyses will be done per stratum, where the data are sufficient. If the data do not meet the assumptions of normality, Friedman's test

2013 Clinical Trials

99. The impact of human immunodeficiency virus-related diseases on pigmented skin types. (Abstract)

The impact of human immunodeficiency virus-related diseases on pigmented skin types. Infection with human immunodeficiency virus (HIV) remains a significant problem globally. Early diagnosis and treatment with antiretroviral drugs has considerably improved health outcomes and decreased disease-related morbidity. HIV infection is associated with a wide range of skin disorders enabling dermatologists to diagnose HIV as well as associated opportunistic infections early in the course of disease (...) . Despite concerted efforts by international health organizations to limit disease incidence, the prevalence of HIV infection remains high and is highest in sub-Saharan Africa. The diagnosis of HIV-related skin diseases is challenging as immunosuppression often results in atypical disease presentation. In addition, the clinical presentation will vary in pigmented skin types. The aim of this article is to describe disease variation in pigmented skin types. © 2013 The Author BJD © 2013 British Association

2013 British Journal of Dermatology

100. Recalcitrant pseudotumoral anogenital herpes simplex type 2 in Human Immunodeficiency Virus-Infected Patients: Evidence for predominant B-lymphoplasmocytic infiltration and immunomodulators as effective therapeutic strategy. Full Text available with Trip Pro

Recalcitrant pseudotumoral anogenital herpes simplex type 2 in Human Immunodeficiency Virus-Infected Patients: Evidence for predominant B-lymphoplasmocytic infiltration and immunomodulators as effective therapeutic strategy. In patients with human immunodeficiency virus (HIV) infection, genital herpetic lesions may be extensive and tend to persist for longer periods; in addition, atypical hypertrophic, ulcerative, or pseudotumor forms have been reported, frequently showing resistance (...) 2 cases, and the immunomodulators imiquimod and thalidomide allowed 5 patients to reach sustained complete response.HSV-2-related pseudolymphoma in HIV-infected patients is characterized by a predominant polyclonal lymphoplasmacytic infiltration, and is frequently refractory to antiherpetic drugs. Immunomodulatory therapeutic strategies using thalidomide showed consistent efficacy, and should be considered early during the course of disease.

2013 Clinical Infectious Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>